The probability of the Bayer-MON deal closing hasn't changed appreciably in the past few months insofar as the key regulatory approvals, especially the EU and China, remain.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”